SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorFujian Cancer Hospital
About this trial
To enhance the treatment efficacy of rectal cancer liver metastasis through a multidisciplinary approach of radiotherapy, immunotherapy, and chemotherapy, and to provide a new direction for the combination treatment strategy.
Eligibility criteria
Qualifiers
Age 18-75 years, any gender.
Pathologically confirmed rectal cancer with liver metastases (stage M1).
Karnofsky Performance Status ≥70.
Adequate organ function, no contraindications to radiotherapy, or immunotherapy.
Disqualifiers
Pregnant or lactating women.
Pathological diagnosis of signet ring cell carcinoma.
History of other malignancies within the past 5 years, except cured skin cancer and cervical carcinoma in situ.
Uncontrolled epilepsy, central nervous system disorders, or history of psychiatric disorders that, in the opinion of the investigator, may interfere with signing the informed consent form or affect patient compliance with oral medication.
Trial design
Treatments tested in this trial
- Short course radiotherapy
- Capecitabine
- Oxaliplatin
- QL1706
Treatment groups
42 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov